Vor Biopharma Adds Industry Veteran David Zaccardelli to Board
I'm LongbridgeAI, I can summarize articles.Vor Biopharma announced that board member Andrew Levin resigned effective July 6, 2026, without disagreement. Subsequently, on July 7, the company appointed David Zaccardelli as an independent Class II director through 2029 to fill the vacancy. Zaccardelli brings significant experience from public pharmaceutical companies. The appointment follows standard governance practices and aims to strengthen the company's strategic positioning.
4th of July Sale - 70% Off
- Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
- Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.
Vor Biopharma ( (VOR) ) has issued an update.
On July 6, 2026, Vor Biopharma announced that Board member Andrew Levin, M.D., Ph.D., resigned effective immediately, with the company noting his departure did not stem from any disagreement. The Board expressed appreciation for his service, indicating a routine transition rather than a governance dispute.
On July 7, 2026, the Board filled the vacancy by appointing David Zaccardelli, Pharm.D., as an independent Class II director through the 2029 annual meeting, adding significant experience from his leadership roles at multiple public pharmaceutical companies. Zaccardelli will receive standard non-employee director cash and equity compensation, underscoring that the appointment follows normal corporate governance and may strengthen Vor Biopharma’s strategic and industry positioning.
The most recent analyst rating on (VOR) stock is a Buy
with a $31.00 price target.
To see the full list of analyst forecasts on Vor Biopharma stock,
see the VOR Stock Forecast page.
Spark’s Take on VOR Stock
According to Spark, TipRanks’ AI Analyst, VOR is a Neutral.
The score is held down primarily by weak financial performance (no revenue, widening losses, sustained cash burn, and negative equity indicating financing dependence). Offsetting this, technicals show strong momentum above major moving averages, and recent corporate updates were positive (governance support and a telitacicept approval-related milestone). Valuation remains challenged due to negative earnings and no dividend support.
To see Spark’s full report on VOR stock,
click here.
More about Vor Biopharma
Vor Biopharma Inc. is a biotechnology company operating in the pharmaceutical sector, with a focus on developing innovative therapies. Its governance structure is overseen by a Board of Directors that includes independent members drawn from across the biopharma and drug development industries.
The company’s board composition reflects an emphasis on experience in clinical research, drug development, and commercial pharmaceutical operations, as demonstrated by its selection of directors with backgrounds in managing public pharma companies and bringing products through development to market.
Average Trading Volume: 1,174,236
Technical Sentiment Signal: Hold
Current Market Cap: $1.12B